Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 13/20 | 0.43 |
| ▸ | CX3CR1 | P49238 | 2/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5499308 | 0.89 | CXCR2 (0.43) | CXCR2CX3CR1CXCR1 | |
| SCHEMBL5491796 | 0.80 | CXCR2 (0.45) | CXCR2CX3CR1HTR1BALDH1A1POLB | |
| SCHEMBL5500216 | 0.78 | RAB9A (0.47) | CXCR2ALDH1A1POLBGAAMEN1 | |
| SCHEMBL490197 | 0.69 | CXCR2 (0.49) | CXCR2CX3CR1HTR1BGAAMEN1 | |
| SCHEMBL5500266 | 0.69 | CXCR2 (0.53) | CXCR2CX3CR1HTR1B | |
| SCHEMBL490086 | 0.69 | MPO (0.48) | CXCR2CX3CR1HTR1BALDH1A1POLB | |
| SCHEMBL5497236 | 0.67 | CXCR2 (0.49) | CXCR2CX3CR1CXCR1 | |
| SCHEMBL489580 | 0.67 | CXCR2 (0.50) | CXCR2CX3CR1HTR1BGAAMEN1 | |
| SCHEMBL3854052 | 0.67 | CXCR2 (0.54) | CXCR2CX3CR1HTR1BALDH1A1MEN1 | |
| SCHEMBL1487257 | 0.64 | CXCR2 (0.48) | CXCR2CX3CR1HTR1BALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328319-B1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| US-7071193-B2 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | ASTRAZENECA AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20040102447-A1 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102447-A1 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | CXCR3, CXCR2, CCR2 | CXCR2 2/4885CX3CR1 29/4885HTR1B 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.